PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the House Committee on Energy and Commerce.
Congressional Research Service
No official summary is available in the imported record yet.
People & committees
Rep. Harshbarger, Diana [R-TN-1] · R–TN
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
Source last updated: Feb 5, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1794 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1794 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1794 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1794 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-03-03 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
The proposed United States-Abraham Accords Cooperation and Security Act of 2025 would create a Food and Drug Administration (FDA) office in a country that signed the Abraham Accords Declaration. The office would help participating countries’ regulators strengthen product oversight and align regulatory requirements. It would also help interested parties understand U.S. regulatory processes and exchange feedback about product research, development, and manufacturing.
This Act may be cited as the United States-Abraham Accords Cooperation and Security Act of 2025.
(A) select the location of the Abraham Accords Office in an Abraham Accords country; and (B) establish such office;
provide technical assistance to regulatory partners in Abraham Accords countries on strengthening regulatory oversight and converging regulatory requirements for the oversight of regulated products
facilitate interactions between the Food and Drug Administration and interested parties in Abraham Accords countries, including by sharing relevant information regarding United States regulatory pathways with such parties, and facilitate feedback on the research, development, and manufacturing of products regulated in accordance with this Act
the term Abraham Accords country means a country identified by the Department of State as having signed the Abraham Accords Declaration.
The bill would add a new section to the Federal Food, Drug, and Cosmetic Act requiring the Secretary, acting through the FDA Commissioner, to establish the Abraham Accords Office within FDA, headed by a director.
Chapter X of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 391 et seq.) is amended by adding at the end the following: 1015. Abraham Accords Office (a) In general The Secretary, acting through the Commissioner of Food and Drugs, shall establish within the Food and Drug Administration an office, to be known as the Abraham Accords Office, to be headed by a director.
Within two years after enactment of the new section, the Secretary would have to select and establish the office’s location in an eligible country and assign FDA staff as the Secretary determines necessary. Site selection and establishment would require consultation with participating governments and appropriate U.S. diplomatic and security personnel.
Not later than 2 years after the date of enactment of this section, the Secretary shall— (1) in consultation with the governments of Abraham Accords countries, as well as appropriate United States Government diplomatic and security personnel— (A) select the location of the Abraham Accords Office in an Abraham Accords country; and (B) establish such office; and (2) assign to such office such personnel of the Food and Drug Administration as the Secretary determines necessary to carry out the functions of such office.
Eligibility would depend on the State Department identifying a country as having signed the Abraham Accords Declaration. The same definition would apply to the required congressional report.
the term Abraham Accords country means a country identified by the Department of State as having signed the Abraham Accords Declaration.
In this subsection, the term Abraham Accords country has the meaning given such term in section 1015(d) of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)).
After the office was established, the Secretary, acting through its director, would have to provide technical assistance to participating countries’ regulators. This would cover stronger oversight, closer alignment of regulatory requirements, and good manufacturing practices—the standards governing how products are manufactured—including issues involving FDA-regulated medical products.
The Secretary, acting through the Director of the Abraham Accords Office, shall— (1) after the Abraham Accords Office is established— (A) as part of the Food and Drug Administration’s work to strengthen the international oversight of regulated commodities, provide technical assistance to regulatory partners in Abraham Accords countries on strengthening regulatory oversight and converging regulatory requirements for the oversight of regulated products, including good manufacturing practices and other issues relevant to manufacturing medical products that are regulated by the Food and Drug Administration
The office would also have to facilitate communication between FDA and interested parties in eligible countries, share information about U.S. regulatory processes, and facilitate feedback on regulated products’ research, development, and manufacturing. The Secretary would determine what additional activities were necessary to carry out the section.
(B) facilitate interactions between the Food and Drug Administration and interested parties in Abraham Accords countries, including by sharing relevant information regarding United States regulatory pathways with such parties, and facilitate feedback on the research, development, and manufacturing of products regulated in accordance with this Act; and (2) carry out other functions and activities as the Secretary determines to be necessary to carry out this section.
The new section would not require any action inconsistent with a federal national security recommendation.
Nothing in this section shall be construed to require any action inconsistent with a national security recommendation provided by the Federal Government.
Within three years after enactment, the Secretary of Health and Human Services would have to report to Congress. The report would evaluate manufacturers’ progress toward meeting FDA requirements, count parties helped with interactions or feedback, summarize technical assistance, and recommend improvements in coordination. Requiring an evaluation does not establish that the office would achieve those results.
Not later than 3 years after the date of enactment of this Act, the Secretary of Health and Human Services shall submit to the Congress a report on the Abraham Accords Office, including— (A) an evaluation of how the Office has advanced progress toward conformance with Food and Drug Administration regulatory requirements by manufacturers in the Abraham Accords countries; (B) a numerical count of parties that the Office has helped facilitate interactions or feedback pursuant to section 1015(c)(1)(B) of the Federal Food, Drug, and Cosmetic Act (as added by subsection (a)); (C) a summary of technical assistance provided to regulatory partners in Abraham Accords countries pursuant to subparagraph (A) of such section 1015(c)(1); and (D) recommendations for increasing and improving coordination between the Food and Drug Administration and entities in Abraham Accords countries.
The supplied actions snapshot, updated February 5, 2026, records introduction in the House and referral to the House Committee on Energy and Commerce on March 3, 2025.
Source snapshot updated 2026-02-05T17:34:05Z. 2025-03-03: Referred to the House Committee on Energy and Commerce. 2025-03-03: Introduced in House
A closer look
Reviewed version: Introduced in House · 2025-03-03. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy change attached to appropriations was identified in the complete supplied introduced text. This conclusion does not establish absence in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for a particular recipient or place was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish formal earmark status in absent accompanying materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No separate narrow carve-out, special exemption, or preferential exception was identified in the complete supplied introduced text. Its geographic program scope defines its intended participants and does not alone warrant a targeted-benefit finding. This conclusion is limited to that version.
Full text preserved for this analysis. Legislative record snapshot: Feb 5, 2026. How PlainBill uses AI